BMS Sighs In Relief As Opdivo Returns To Sales Growth

 
• By Joseph Haas

With full-year 2020 and Q1 sales down due to pandemic, the company celebrates the PD-1 therapy’s growth in Q2. CAR-T products Breyanzi, Abecma are off to solid launches but face manufacturing hurdles.

Bristol-Myers-Squib_685347493_1200.jpg
BMS reports 16% year-over-year sales growth for Q2 2021

More from Earnings

More from Business